Cingulate (CING) to Release Quarterly Earnings on Monday

Cingulate (NASDAQ:CING) will likely be releasing its earnings data before the market opens on Monday, April 7th. Analysts expect Cingulate to post earnings of ($1.48) per share for the quarter.

Cingulate Trading Down 8.0 %

CING stock opened at $3.78 on Friday. Cingulate has a 1-year low of $1.80 and a 1-year high of $20.83. The business’s 50 day simple moving average is $4.19 and its 200 day simple moving average is $4.42. The firm has a market capitalization of $14.24 million, a PE ratio of -0.26 and a beta of -0.87.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Roth Capital upgraded shares of Cingulate to a “strong-buy” rating in a report on Friday, January 10th. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Cingulate in a research note on Thursday, March 6th. Finally, Roth Mkm began coverage on shares of Cingulate in a report on Friday, January 10th. They issued a “buy” rating and a $12.00 price target on the stock.

Cingulate Company Profile

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.